The most expensive drugs in the world — starting at the low price of $1 million: The majority of these drugs treat illness affecting less than 200,000 people
qz.com/most-expensive-drugs-2024-lenmeldy-hemgenix-elevidys-1851356958
Paid articlePaid
U.S. FDA to not conduct advisers' meet for Sarepta's Duchenne gene therapy: Sarepta Therapeutics said on Friday that the U.S. FDA will not conduct a meeting of ...
reut.rs/48lpFt2
Quick Glance: Ex-FBI Informant Charged with Lying about Joe Biden and Son
- The U.S. special counsel leading a criminal probe into President Joe Biden's son, Hunter Biden, charged a former FBI informant for lying about their alleged involvement in business dealings with Ukrainian energy company Burisma Holdings.
- A federal grand jury indicted Alexander Smirnov, 43, for making false statements and creating a false record in relation to an FBI probe.
- The indictment states that Smirnov falsely recounted meetings where Burisma executives claimed to have hired Hunter Biden to solve problems through his father.
- Smirnov falsely claimed that Burisma executives paid $5 million to Joe Biden and Hunter Biden for his son to address issues through his father during a criminal investigation.
Prospects Look Better for Sarepta Gene Therapy, Sending the Stock Up Again: Investors looking for signs the FDA will let more patients use Sarepta Therapeutics’ ...
on.barrons.com/42MlPbh
Paid articlePaid
Get expert insight on how to develop a transition of care plan for patients with spinal muscular atrophy moving from pediatric to adult care ... Show more
Sarepta Therapeutics: Leading The Way In DMD Treatment With Gene Therapy Innovations
seekingalpha.com/article/4664594-sarepta-therapeutics-leading-the-way-in-dmd-treatment-with-gene-therapy-innovations
Paid articlePaid
Sarepta Rebounded. Its Gene Therapy Is Back on Course.
barrons.com/articles/sarepta-stock-rebounded-fda-dmd-b21876ed
Paid articlePaid
Sarepta's new Duchenne drug outperforms bestseller Exondys in trial: Sarepta Therapeutics (SRPT.O) said on Monday its new experimental drug for Duchenne muscular ...
reuters.com/business/healthcare-pharmaceuticals/sarepta-says-its-experimental-duchenne-drug-more-effective-than-older-medicine-2024-01-29/
Sarepta's new Duchenne drug outperforms bestseller Exondys in trial: Sarepta Therapeutics (SRPT.O) said on Monday its new experimental drug for Duchenne muscular ...
reuters.com/business/healthcare-pharmaceuticals/sarepta-says-its-experimental-duchenne-drug-more-effective-than-older-medicine-2024-01-29/
4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024: 4D Molecular Therapeutics (FDMT): Seveal catalysts/value inflection points in 2024 ...
seekingalpha.com/article/4664889-4d-molecular-therapeutics-several-value-inflection-points-to-watch-in-2024
Paid articlePaid
Sarepta defeats Regenxbio, UPenn patent lawsuit over muscular dystrophy treatment
reuters.com/legal/litigation/sarepta-defeats-regenxbio-upenn-patent-lawsuit-over-muscular-dystrophy-treatment-2024-01-05/
Dyne's shares jump after promising data on muscle disorder treatment: Shares of drug developer Dyne Therapeutics (DYN.O) jumped 18% on Wednesday after its ...
reuters.com/business/healthcare-pharmaceuticals/dynes-shares-surge-after-promising-data-muscle-disorder-treatment-2024-01-03/
Douglas S. Ingram, President and Chief Executive Officer of Sarepta Therapeutics, joined Alex Knapp to discuss innovation in detecting ... Show more
Sarepta (SRPT) to Seek Approval for DMD Therapy Even After Drug Trial Failed: Normally when a drug fails to show a clear effect in a final-stage trial ...
bloomberg.com/news/articles/2023-10-31/after-drug-trial-fizzles-sarepta-still-seeks-broader-approval
Sarepta Crashes 45% After Its Gene Therapy Flops Its Biggest Test: Sarepta Therapeutics' gene therapy, Elevidys, faces an uphill regulatory journey ...
investors.com/news/technology/srpt-stock-halted-after-sarepta-unveils-mixed-results-for-duchenne-gene-therapy/
These insiders were big buyers this week, including in one beaten-up biotech: CNBC Pro screened for the five U.S. companies with the biggest insider buying over ...
cnbc.com/2023/11/10/these-insiders-were-big-buyers-this-week-including-in-one-beaten-up-biotech.html
Paid articlePaid
Beware these companies due to report earnings that have negative profit momentum: Analysts have been cutting earnings estimates for these four stocks ahead of ...
cnbc.com/2023/11/09/beware-these-companies-due-to-report-but-that-have-negative-momentum.html
Paid articlePaid
Biotech Stocks Near An Inflection Point In Gene Therapy: The big names behind biotech stocks want to cure diseases, not just treat them. Gene therapy drugs are ...
investors.com/news/technology/biotech-stocks-near-a-significant-inflection-point-in-gene-therapy-but-watch-your-wallet/
First gene therapy for deadly form of muscular dystrophy gets FDA approval for young children
pbs.org/newshour/health/first-gene-therapy-for-deadly-form-of-muscular-dystrophy-gets-fda-approval-for-young-kids
Quick Glance: FDA Approves Sarepta's Gene Therapy for Rare Muscular Dystrophy
- The US health regulator has granted accelerated approval to Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy (DMD).
- Initially seeking approval for DMD patients who can walk.
- Sarepta's gene therapy was able to produce a mini version of the dystrophin protein, but did not improve patient clinical outcomes.
- Approval for Sarepta's treatment could open doors for more effective gene therapies.
First Gene Therapy for Muscular Dystrophy Approved: The drug, from Sarepta Therapeutics, promises to repair the defective gene at the root of the fatal disorder ...
wsj.com/articles/first-gene-therapy-for-muscular-dystrophy-approved-34860988
Sarepta says FDA may limit gene therapy nod to smaller population, shares fall: Sarepta Therapeutics Inc (SRPT.O) said the U.S. drug regulator could initially ...
reuters.com/business/healthcare-pharmaceuticals/fda-defers-decision-sareptas-gene-therapy-june-22-2023-05-24/
Sarepta surges after FDA panel backs Duchenne gene therapy: Shares of Sarepta Therapeutics (SRPT.O) jumped 25% on Monday as a backing by the U.S ...
reuters.com/business/healthcare-pharmaceuticals/sarepta-surges-after-fda-panel-backs-duchenne-gene-therapy-2023-05-15/
Sarepta surges after FDA panel backs Duchenne gene therapy: Shares of Sarepta Therapeutics (SRPT.O) jumped 25% on Monday as a backing by the U.S ...
reuters.com/business/healthcare-pharmaceuticals/sarepta-surges-after-fda-panel-backs-duchenne-gene-therapy-2023-05-15/
Drug Companies Are Minting Billions on Unproven Treatments With FDA Shortcut: Accelerated approvals have helped get promising therapies to market fast — but ...
bloomberg.com/news/articles/2023-05-14/fda-fast-tracked-drugs-make-companies-billions-on-unproven-claims
FDA advisers narrowly back first gene therapy for muscular dystrophy: A panel of experts voted 8-6 in favor of Food and Drug Administration approval of the first ...
npr.org/sections/health-shots/2023/05/12/1175852294/fda-advisers-narrowly-back-first-gene-therapy-for-muscular-dystrophy
FDA advisers narrowly vote in favor of experimental gene therapy for rare muscle disease
cnn.com/2023/05/12/health/duchenne-muscular-dystrophy-therapy-fda/
Sarepta drops as report says FDA almost rejected under-review gene therapy: Sarepta Therapeutics Inc's shares (SRPT.O) fell more than 6% on Thursday as Stat News ...
reuters.com/business/healthcare-pharmaceuticals/sarepta-shares-drop-report-says-fda-almost-rejected-under-review-gene-therapy-2023-04-13/
Gene therapy for muscular dystrophy stirs hopes and controversy: The FDA is considering greenlighting the experimental treatment under its accelerated approvals ...
npr.org/sections/health-shots/2023/05/02/1171357002/gene-therapy-for-muscular-dystrophy-stirs-hopes-and-controversy
Sarepta slides as FDA about-turn on panel clouds gene therapy approval path: Shares of Sarepta Therapeutics Inc (SRPT.O) slumped as much as 21% on Friday on ...
reuters.com/business/healthcare-pharmaceuticals/sarepta-slides-surprise-fda-panel-meeting-adds-uncertainty-gene-therapy-2023-03-17/
Here are Tuesday's biggest analyst calls: Apple, Amazon, Boeing, Chipotle, Rivian, Etsy, Exxon & more
cnbc.com/2023/04/04/tuesdays-top-wall-street-analyst-calls-include-xom-and-etsy.html
Paid articlePaid
Here are Wednesday's biggest analyst calls: Apple, Procter & Gamble, Tesla, Spotify, AbbVie & more
cnbc.com/2023/03/01/wall-streets-top-analyst-calls-on-wednesday-include-apple-spotify.html
Paid articlePaid
Citi says the recent sell-off in this biotech stock is 'overdone,' predicts shares can rally 30% from here
cnbc.com/2023/04/04/citi-says-the-recent-selloff-in-this-biotech-stock-is-overdone.html
Paid articlePaid
Sarepta Breaks Out As FDA Smooths The Path For Its Gene Therapy: Sarepta could snag an accelerated approval for its muscular dystrophy gene therapy ...
investors.com/news/technology/srpt-stock-breaks-out-as-fda-smooths-the-path-for-its-gene-therapy/
ASX: $ANP 📓 An #Upcoming US #Study ? Internal Changes? ~ Updates & Insights With #MarkDiamond , CEO! #AntisenseTherapeutics is a #biotech co. developing & commercializing antisense ... Show more
Wall Street ends down sharply, hit by Apple and China worries: U.S. stocks ended sharply lower on Monday after protests in major Chinese cities against strict ...
reuters.com/markets/us/wall-st-futures-slip-china-covid-woes-apple-falls-2022-11-28/
Quick Glance: China's Deadly Fires Fuel Protests Against Xi's Covid Policies
- Travel restrictions and government restrictions on international journalists make it impossible to report on the protests.
- "We want freedom," they declared.
- For the most part, since Covid spread from Wuhan about three years ago, many Chinese have accepted severe regulations, including extensive travel restrictions, as a price for avoiding the widespread illness and death that the United States and other countries experienced.
- The Chinese authorities is likely to be concerned that photographs and footage of the Shanghai protests may spread over online control, inciting further upheaval.
Here are Thursday's biggest analyst calls: Apple, GameStop, First Solar, Boeing, Moderna & more
cnbc.com/2022/09/08/thursday-street-calls-apple-gamestop-first-solar-boeing-moderna-.html
Paid articlePaid
Ray Dalio on a buying spree - he bought these three stocks: Hedge fund manager legend Ray Dalio has been on a buying spree. But which stocks are particularly ...
boerse-online.de/nachrichten/aktien/ray-dalio-auf-einkaufstour-diese-drei-aktien-hat-er-gekauft-1031695286
Wall Street pros say these small caps are good buys as recession looms — BofA gives one 40% upside
cnbc.com/2022/08/03/wall-street-small-cap-stocks-that-could-outperform-in-a-recession.html
Paid articlePaid
Stocks making the biggest moves after hours: FedEx, Sarepta Therapeutics and more
cnbc.com/2022/06/23/stocks-moving-after-hours-fedex-sarepta-therapeutics-and-more.html
New to NewsWall?
Sign up now to get your own personalized news!
Trending topics